Nondisabling relapses that occur early in the course of relapsing-remitting multiple sclerosis (RRMS) signal faster accumulation of disability relative to no early relapses, new research suggests.

Basel, 21 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the Phase III METEOROID study ...

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple ...

A committee in the EU recommended that tolebrutinib, to be sold as Cenrifki, be approved for people with SPMS with no relapses for two years.

A young man in recovery from addiction once gave me his perspective on the painful consequences of relapse: “It’s not the relapse that troubles me,” he said. “It’s the self-beating that comes ...

Roche Holding AG’s experimental multiple sclerosis pill roughly halved the number of disease relapses in two key late-stage ...

Patients were given up to 9 weeks of pembrolizumab prior to surgery, instead of the usual surgery followed by 3 to 6 months ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the Phase III METEOROID study demonstrating that Enspryng® (satralizumab) reduced the risk of a new ...

These results underscore that fenebrutinib has potential as a high-efficacy oral treatment for RMS. Its unique mode of action may offer a differentiated profile by targeting dual drivers of MS within ...

Relapse isn’t inevitable, and it’s certainly a different story for every individual. However, it is very often part of the recovery journey. Garrett Tardif, the director of Admissions at Crestview ...